首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1143411

2022-2029 年植入式输液泵的全球市场

Global Implantable Infusion Pumps Market - 2022-2029

出版日期: 2022年10月26日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球植入式输液泵市场预计在 2021 年达到 148.93 亿美元，到 2029 年达到 226.45 亿美元，在预测期间（2022-2029 年）以 5.7% 的复合年增长率增长。

植入式输液泵是一种使用细而灵活的导管控制液体和药物输送到患者身体特定区域的装置。医生可以用它来治疗各种疾病，包括肌肉痉挛、糖尿病和慢性疼痛。

市场动态

全球植入式输液泵市场的增长受到多种因素的推动，例如癌症和糖尿病等慢性病患病率的上升、重大的技术进步以及各种新产品的推出。

慢性病患病率的增加和技术进步的不断提高预计将推动市场增长。

推动市场增长的主要因素是癌症和糖尿病等慢性病的高患病率，尤其是在老年人中，以及技术的不断进步。

根据美国国家公共卫生研究所的数据，到 2022 年，癌症将成为全球第二大死因，登记的新病例约为 1,918,030 例。癌症导致全球 609,360 人死亡。此外，根据世卫组织的公告，预计到 2030 年，新病例的数量将增加约 70%。使用最新的植入式输液泵可以有效地管理各种药物，并且它们在癌症患者中的使用正在全球范围内取得进展。

慢性疾病也需要植入式输液泵。根据加州大学的一项研究，全世界约有 500 万人患有终末期肾病 (ESRD)。被诊断出患有这种疾病的人数预计将以每年 5-7% 的速度增长。根据国际糖尿病联合会的数据，全世界约有 4.63 亿 20-79 岁的成年人患有糖尿病。预计到 2045 年，这一数字将增加并达到 7 亿。

多个组织、团体和研究机构加大力度改进植入式输液泵和解决安全问题，预计将刺激市场增长。例如，美国食品和药物管理局 (FDA) 发起了一项改进计划，以解决植入式输液泵的安全问题，并鼓励整个行业开发更安全、更有效的输液泵。FDA 对植入式输液泵製造商制定了额外要求，以识别设计缺陷并在安全之前对其进行纠正，要求製造商提交额外的设计和工程作为其上市前提交的一部分。我们已提供信息并决定进行额外测试的设备。FDA 与研究机构、外国监管机构和製造商合作，以促进更安全、更有效的输液泵的开发。FDA 正在提高医院工作人员、管理人员和家庭用户对减轻与使用现有输液泵相关的风险的认识。

预计患者安全问题和输液不足将阻碍市场增长。

患者安全因素，特别是围绕磁共振、频繁的产品召回、严格的法规以及导致严重后果的不当注射将阻碍市场的增长。2019 年 12 月发表的一项题为“输液泵用药错误风险”的研究报告了宾夕法尼亚州 132 家医院发生的与输液泵使用和用药错误相关的总共 1,004 起事件。这些事件中有 22% 与高度警告药物有关。大多数事件是良性的，不会导致严重伤害或死亡。

细分分析

活塞式输液治疗领域预计将占全球植入式输液泵市场的最大市场份额。

活塞输液治疗领域预计将拥有积极的市场份额，因为它越来越多地融入到体内的药物输送中。活塞输液泵的工作原理类似于汽车中的活塞。随着活塞的前进，会释放出微量的药物。活塞式输液泵需要专门开发的输液管。这种管通常包含带有柱塞的药筒。这些输液设备高效且准确。推荐用于易碎液体等产品。

癌症发病率上升是市场增长的主要驱动力。越来越多的公司正在开髮用于输液的植入式输液泵。Medtronic、Smiths Medical、Epic Medical 和 Boston Scientific Corporation 被称为用于药物输送的植入式输液泵的领先製造商。例如，在 2021 年 4 月，B. Brown 与 Online Suite plus 相结合，这是一种提供连接、数据管理、基于云的应用程序、卓越的处理、续订灵活性等多种好处的生态系统。我们正在推出创新的输液泵“Space Plus”。

区域分析

北美在全球植入式输液泵市场占有最大的市场份额。

北美是植入式输液泵的主要市场，占主要收入份额。根据美国卫生与公众服务部的数据，2010 年美国国家癌症治疗支出将达到近 1250 亿美元，2020 年将达到 1560 亿美元。造成这种情况的原因包括医疗设施的改善、医疗基础设施的显着发展、癌症、心血管疾病、终末期肾病的患病率增加以及人口老龄化。

主要参与者的各种技术进步正在扩大市场。例如，Epic Medical Limited 的 SMARTeZ 泵可以通过弹性膜施加的正压向患者输送药物。该泵由两层硅胶膜构成，以提高流量精度并减少输液结束时的残留量。此外，这款弹性输液泵还提供了一个移动应用程序，以改善患者在不同地点或家中的治疗效果。VSCAN 可以评估泵中剩余的药物量。SMARTeZ Chemo CS 应用程序可以通过其内置的药物库帮助消除人为错误并提高患者安全性。

竞争格局

由于多个国际和区域市场，全球数字植入式输液泵市场竞争激烈。产品多样化、创收和机会使市场更具竞争力。全球植入式输液泵市场的主要参与者有 Medtronic PLC、Codman 和 Shurtleff、I-Flow Corp/Halyard Health、Flowonix Medical、Tricumed Medizintechnik、Intera Oncology、Tandem Diabetes Care Inc、Smith's Medical、B. Braun、Terumo Corporation、Ambu Inc.、Medtronic PLC、Concordman 和 Shurtlef。

主要参与者正专注于促进全球市场增长的关键战略，例如合作、收购和产品发布。例如：

2022年1月， Smiths Medical被ICU Medical Co., Ltd.从Smiths Group手中收购。流动输液设备和血管通路是 Smith 的医疗业务，与 ICU 目前的业务相结合，将使我们成为输液治疗的领先供应商。
2021 年 4 月，医疗器械製造商 Smiths Medical 将把 Parkview Health 的输液管理系统——FarmGuard 与其电子健康记录系统集成，在所有医院之间实现双向互操作。这种集成通过自动记录实现智能泵编程。
2020 年 11 月，Ambu Inc. 宣布与 Intalere 就疼痛护理管理解决方案达成协议。Intalere 将收到 Ambu ACtion TM 止痛泵。
2020年2月，LTR Medical与Woo Young Medical签署独家经销协议，向澳大利亚市场经销新一代弹性体注射技术。

值得关注的重点公司

Medtronic PLC

概述 MedtronicPLC，总部位于美国明尼阿波利斯，生产和销售输液泵、导管、支架、胰岛素笔和血糖监测系统等医疗器械，是一家拥有员工的医疗器械製造商。

产品介绍

Syncromed II 植入式泵。该设备是一种可编程输液泵，可通过植入导管在鞘内输送药物。它用于慢性疼痛管理，可以通过称为控制工作流程的技术进行控制。这种方法是专门为缓解疼痛和去除全身性阿片类药物而开发的。

重大发展。2022 年 5 月，医疗保健技术公司 Medtronic plc 宣布其药物洗脱支架 Onyx Frontier 获得美国食品和药物管理局的批准。它是 Resolute DES 系列的最新创新。该支架具有改进的输送系统，可提供更好的性能和可输送性。

全球植入式输液泵市场报告提供了大约 45多个市场数据表、40 多个数字和 180 页的结构。

Market Overview

The Global Implantable Infusion Pumps Market was valued at US$ 14,893 million in 2021 and is estimated to reach US$ 22,645 million by 2029, growing at a CAGR of 5.7 during the forecast period (2022-2029).

The implantable infusion pump is a device used to deliver fluids and medications into a particular part of a patient's body with the help of a flexible and thin catheter in a controlled manner. Healthcare practitioners may use them for various treatments such as muscle spasticity, diabetes and chronic pain.

Market Dynamics

The global implantable infusion pumps market growth is driven by several factors, including the rising prevalence of chronic diseases such as cancer and diabetes, significant technological advancements, and various new product launches.

The increasing prevalence of chronic diseases and rising technological advancements are expected to drive market growth.

The major drivers of increasing market growth are the high prevalence of cancer and chronic diseases such as diabetes, especially in geriatric patients and increasing technological advancements.

According to National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO, the number of new cases is expected to rise by around 70% by 2030. The administration of a variety of drugs is efficient with the help of the latest implantable infusion pumps, and there is a rise in the adoption of these infusion pumps by cancer patients globally.

Even chronic diseases require implantable infusion pumps; According to a study by the University of California, around 5 million people worldwide are affected by end-stage renal disease (ESRD). The number of patients diagnosed with the disease is expected to increase at a rate of 5-7% annually. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 have diabetes worldwide. This number is expected to increase and reach up to 700 million by 2045.

The rising initiatives of several organizations, associations, and institutes to improve the implantable infusion pump and address safety concerns shall stimulate market growth. For instance, the U.S. Food and Drug Administration (FDA) launched an improvement initiative to address implantable infusion pump safety problems and foster the development of safer, more effective infusion pumps across the industry. The FDA established the additional requirements for implantable infusion pump manufacturers to identify the design deficiencies and correct them before they lead to safety; they provide additional design and engineering information as part of its premarket submissions and conduct additional testing of its devices. The FDA collaborated with institutes, foreign regulatory bodies, and manufacturers to facilitate the development of safer and more effective infusion pumps. The FDA is creating awareness regarding mitigating the risks associated with using existing infusion pumps among hospital staff, administrators, and home users.

Patient safety concern and the improper infusion is expected to hamper the market growth.

The factors concerning patient safety, especially in magnetic resonance surroundings, frequent recalls of products, stringent regulations and improper infusion leading to severe consequences will hamper the market's growth. A study published in Dec 2019, titled "Risk of Medication Errors with Infusion Pumps," reported a total of 1,004 events related to the use of infusion pumps and medication errors that occurred in 132 hospitals in Pennsylvania. 22% of these incidents were related to high-alert medication. Most events were less harmful and didn't lead to serious harm or death.

Segment Analysis

Piston type infusion therapy segment is expected to hold the largest market share in the global implantable infusion pumps market.

The piston-type infusion therapy segment is expected to have a positive market share due to its rising uptake for drug delivery into the body. Piston-driven infusion pumps work similarly to automobile pistons. A minute amount of medicine is released when the piston goes forward. Piston-type pumps need IV tubing specially developed for the device. Generally, such kind of tubes contains a cartridge with a plunger. These devices for intravenous infusion are very efficient as well as accurate. It is highly recommended for products such as fragile fluids.

The increasing cancer incidence is the main factor in the market's growth. There is an increase in companies developing implantable infusion pumps for infusions. Medtronic, Smith's Medical, Epic Medical, and Boston Scientific Corporation are the major players in implantable infusion pumps for drug infusion. For instance, in April 2021, B. Braun launched Space plus, a novel infusion pump combined with Online Suite plus, a kind of ecosystem that provides various benefits, including connectivity, data management, cloud-based applications, excellent therapy, and update flexibility.

Geographical Analysis

North America holds the largest market share in the global implantable infusion pumps market.

North America is the leading market for implantable infusion pumps and accounts for a major revenue share. According to the U.S. Department of Health and Human Services, national expenditures for cancer treatment in the U.S. were nearly US$ 125 billion in 2010 and US$ 156 billion by 2020. The reasons are improved medical facilities, greatly developed healthcare infrastructure, rising cancer, cardiovascular, end-stage renal diseases and the growing geriatric population.

Various technological advancements by key players are increasing the market. For instance, Epic Medical Limited's SMARTeZ Pump allows the medication to be delivered to the patient by positive pressure applied by the elastomeric membrane. It comprises 2 layers of silicone membranes for improving the flow accuracy and reducing the residual volume when the infusion is complete. Moreover, the Mobile Apps are available along with this Elastomeric Infusion Pump to improve patient-user outcomes in alternate sites and at home VSCAN and Chemo C.S. App. VSCAN provides an assessment of the volume of medication remaining in the pump. SMARTeZ Chemo C.S. App helps eliminate human errors and improves patient safety with its onboard drug library.

Competitive Landscape

The global digital implantable infusion pump market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Some major key players in the global implantable infusion pumps market are Medtronic PLC, Codman and Shurtleff, I-Flow Corp/Halyard Health, Flowonix Medical, Tricumed Medizintechnik, Intera Oncology, Tandem Diabetes Care Inc., Smith's Medical, B. Braun, Terumo Corporation, Ambu Inc.

The key companies are focusing on key strategies such as collaboration, acquisitions, and product launches which are boosting the growth of the market globally. For instance,

In Jan 2022, Smiths Medical got acquired by ICU Medical Inc from Smiths Group. Ambulatory infusion devices and vascular access are the medical business of Smiths that, combined with ICU's present business, can make it a leading company in infusion therapy.

In Apr 2021, Smiths Medical, a medical device company, announced integrating its infusion management system- PharmGuard, by Parkview Health, with their health record system (electronic) to form interoperability that is bi-directional in all the hospitals. This integration will benefit smart pump programming with auto-documentation.

In Nov 2020, Ambu Inc. announced its contract with Intalere, which will work for pain care management solutions. Intalere is going to receive an Ambu ACTion TM block pain pump.

In February 2020, LTR Medical entered into an exclusive distribution agreement with Woo Young Medical to distribute their new generation of elastomeric infusion technologies into the Australian market.

Key Companies to Watch

Medtronic PLC:

Overview: Medtronic plc is a medical device company that operates in the U.S. and manufactures and markets medical devices such as infusion pumps, catheters, stents, insulin pens, and glucose monitoring systems, with headquarters in Minneapolis, the U.S. It is operational in around 140 countries, and 90,000 people are employed there.

Product Portfolio:

SynchroMed II Implantable Pumps: This device is a programmable infusion pump that, with an implanted catheter, provides drugs in intrathecal space. It is used for chronic pain management and can be controlled using an approach known as Control workflow. This approach is specially developed for giving pain relief and removing systemic opioids.

Key Developments: In May 2022, Medtronic plc, a healthcare technology company, announced its approval of Onyx Frontier, a drug-eluting stent by the United States Food and Drug Administration. It is the latest innovation in the family of Resolute DES. It is an improved delivery system that provides better performance and deliverability.

The global implantable infusion pumps market report would provide access to an approx. 45+ market data table, 40+ figures and 180 pages.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising prevalence of cancer
  - 4.1.1.2. Increasing diabetes and obesity cases
  - 4.1.1.3. Major technological advancements
- 4.1.2. Restraints
  - 4.1.2.1. Factors concerning patient safety and improper infusion
  - 4.1.2.2. Stringent FDA regulations
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Unmet Needs

6. By Product

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Segment
- 6.1.2. Market Attractiveness Index, By Product Segment
6.2. Piston Type Infusion Pumps
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Creeping Type Infusion Pumps

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Segment
- 7.1.2. Market Attractiveness Index, By Application Segment
7.2. Cancer Treatment
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Spasticity Treatment
7.4. Pain Management
- 7.4.1. Non-malignant Pain
- 7.4.2. Malignant Pain
7.5. Diabetes

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty clinics
8.4. Ambulatory Surgical Centres

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia Pacific
9.6. The Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Competitor Strategy Analysis
10.3. Comparative Product Portfolio Analysis
10.4. Market Positioning/Share Analysis
10.5. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Medtronic PLC
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Key Highlights
- 11.1.4. Financial Overview
11.2. Codman and Shurtleff
11.3. I-Flow Corp/Halyard Health
11.4. Flowonix Medical
11.5. Tricumed Medizintechnik
11.6. Intera Oncology
11.7. Tandem Diabetes Care Inc.
11.8. Boston Scientific Corporation
11.9. Terumo Corporation
11.10. B. Braun(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

12.1. Appendix
12.2. About Us and Method of Fixation
12.3. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

2022-2029 年植入式输液泵的全球市场

Global Implantable Infusion Pumps Market - 2022-2029

市场概况

市场动态

慢性病患病率的增加和技术进步的不断提高预计将推动市场增长。

预计患者安全问题和输液不足将阻碍市场增长。

细分分析

活塞式输液治疗领域预计将占全球植入式输液泵市场的最大市场份额。

区域分析

北美在全球植入式输液泵市场占有最大的市场份额。

竞争格局

值得关注的重点公司

Medtronic PLC

产品介绍

目录

第一章 调查方法和范围

第二章市场定义和概述

第三章执行摘要

第四章市场动态

第五章行业分析

第 6 章 按产品分类

第 7 章 按申请

第 8 章最终用户

第9章按地区

第 10 章 竞争格局

第十一章公司简介

第 12 章 数据管理